Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Acquired by State Street Corp

State Street Corp boosted its position in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 0.6% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,459,767 shares of the company’s stock after acquiring an additional 9,090 shares during the quarter. State Street Corp’s holdings in Organogenesis were worth $4,175,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Bank of New York Mellon Corp increased its stake in shares of Organogenesis by 9.4% in the second quarter. Bank of New York Mellon Corp now owns 393,798 shares of the company’s stock worth $1,103,000 after buying an additional 33,990 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Organogenesis by 4,989.9% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock worth $44,000 after buying an additional 15,369 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of Organogenesis by 2.4% in the 2nd quarter. Acadian Asset Management LLC now owns 3,074,375 shares of the company’s stock valued at $8,605,000 after acquiring an additional 72,696 shares during the last quarter. Wealth Dimensions Group Ltd. raised its position in shares of Organogenesis by 435.9% during the 2nd quarter. Wealth Dimensions Group Ltd. now owns 407,965 shares of the company’s stock valued at $1,142,000 after acquiring an additional 331,840 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in shares of Organogenesis by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 269,741 shares of the company’s stock worth $755,000 after buying an additional 9,054 shares during the last quarter. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Organogenesis Stock Down 2.7 %

NASDAQ:ORGO opened at $3.19 on Monday. The firm has a market capitalization of $401.07 million, a PE ratio of -53.17 and a beta of 1.73. Organogenesis Holdings Inc. has a 52 week low of $2.16 and a 52 week high of $4.70. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. The stock has a 50 day moving average of $3.46 and a 200-day moving average of $3.04.

Organogenesis (NASDAQ:ORGO) last issued its earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.11. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The firm had revenue of $115.18 million for the quarter, compared to analyst estimates of $109.59 million. During the same period last year, the company earned $0.02 earnings per share. Analysts predict that Organogenesis Holdings Inc. will post -0.07 EPS for the current year.

Insider Activity at Organogenesis

In related news, CEO Gary S. Gillheeney sold 18,416 shares of Organogenesis stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $3.65, for a total transaction of $67,218.40. Following the sale, the chief executive officer now directly owns 3,400,778 shares in the company, valued at $12,412,839.70. The trade was a 0.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 278,116 shares of company stock worth $991,190 in the last ninety days. 36.90% of the stock is owned by insiders.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.